These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35410368)

  • 1. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy.
    Liu C; Liu X; Xiang X; Pang X; Chen S; Zhang Y; Ren E; Zhang L; Liu X; Lv P; Wang X; Luo W; Xia N; Chen X; Liu G
    Nat Nanotechnol; 2022 May; 17(5):531-540. PubMed ID: 35410368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression Reversal Nanovaccines Substituting Dendritic Cells for Personalized Cancer Immunotherapy.
    Chen H; Cheng H; Liang X; Cai S; Liu G
    Front Immunol; 2022; 13():934259. PubMed ID: 35812415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggregation-Induced-Emission Photosensitizer-Loaded Nano-Superartificial Dendritic Cells with Directly Presenting Tumor Antigens and Reversed Immunosuppression for Photodynamically Boosted Immunotherapy.
    Sun Z; Liu J; Li Y; Lin X; Chu Y; Wang W; Huang S; Li W; Peng J; Liu C; Cai L; Deng W; Sun C; Deng G
    Adv Mater; 2023 Jan; 35(3):e2208555. PubMed ID: 36255149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
    Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
    Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy.
    Wang K; Zhang X; Ye H; Wang X; Fan Z; Lu Q; Li S; Zhao J; Zheng S; He Z; Ni Q; Chen X; Sun J
    Nat Commun; 2023 Oct; 14(1):6748. PubMed ID: 37875481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy.
    Xiong X; Zhao J; Pan J; Liu C; Guo X; Zhou S
    Nano Lett; 2021 Oct; 21(19):8418-8425. PubMed ID: 34546061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
    Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
    Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
    Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
    Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
    Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
    Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Nanovaccine Targeting Clec9a
    Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
    Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
    Bodey B; Siegel SE; Kaiser HE
    In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence.
    Wu K; Lyu F; Wu SY; Sharma S; Deshpande RP; Tyagi A; Zhao D; Xing F; Singh R; Watabe K
    Sci Adv; 2023 Apr; 9(17):eade0625. PubMed ID: 37126558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.
    Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W
    Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
    Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
    Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Situ Antigen-Capturing Nanochaperone Toward Personalized Nanovaccine for Cancer Immunotherapy.
    Li X; Zhang Y; Wu X; Chen J; Yang M; Ma F; Shi L
    Small; 2022 Aug; 18(32):e2203100. PubMed ID: 35843873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering anti-cancer nanovaccine based on antigen cross-presentation.
    Warrier VU; Makandar AI; Garg M; Sethi G; Kant R; Pal JK; Yuba E; Gupta RK
    Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elastic Nanovaccine Enhances Dendritic Cell-Mediated Tumor Immunotherapy.
    Li Q; Teng Z; Tao J; Shi W; Yang G; Zhang Y; Su X; Chen L; Xiu W; Yuwen L; Dong H; Mou Y
    Small; 2022 Aug; 18(32):e2201108. PubMed ID: 35734820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.